These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 12613003)

  • 21. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
    Bremer CT; Lastrapes A; Alper AB; Mudad R
    Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thrombotic microangiopathy in adults].
    Barrientos GJ; Michelangelo H
    Medicina (B Aires); 2006; 66(4):289-95. PubMed ID: 16977962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.
    Cantrell JE; Phillips TM; Schein PS
    J Clin Oncol; 1985 May; 3(5):723-34. PubMed ID: 3923162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha.
    Schlaifer D; Dumazer P; Spenatto N; Mignon-Conte M; Brousset P; Lumbroso C; Cooper M; Muller C; Huguet F; Attal M
    Am J Hematol; 1994 Nov; 47(3):254-5. PubMed ID: 7942805
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemolytic uremic syndrome in patients with Behçet's disease treated with cyclosporin A: report of 2 cases.
    Beaufils H; de Groc F; Gubler MC; Wechsler B; Le Hoang P; Baumelou A; Chomette G; Jacobs C
    Clin Nephrol; 1990 Oct; 34(4):157-62. PubMed ID: 2257701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea.
    Shammas F; Meyer P; Heikkila R; Apeland T; Gøransson L; Berland J; Kjellevold K
    Acta Haematol; 1997; 97(3):184-6. PubMed ID: 9066715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft failure due to hemolytic uremic syndrome recurrence.
    Iaria G; Iorio B; Anselmo A; De Luca L; Tariciotti L; Ielpo B; Muzi F; Lucchesi C; D'Andria D; Orlando G; Del Poeta G; Poggi E; Piazza A; Tisone G
    Transplant Proc; 2006 May; 38(4):1020-1. PubMed ID: 16757250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summaries for patients. Quinine and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
    Ann Intern Med; 2001 Dec; 135(12):S-65. PubMed ID: 11785472
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of hemolytic uremic syndrome accompanied by massive proteinuria and ascites].
    Ookawara S; Saitou M; Suzuki M; Imai H
    Nihon Jinzo Gakkai Shi; 1996 Feb; 38(2):98-102. PubMed ID: 8717312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombotic microangiopathy in advanced prostatic carcinoma.
    Biers SM; Sullivan ME; Roberts IS; Noble JG
    Urology; 2004 Feb; 63(2):380-2. PubMed ID: 14972503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemolytic uremic syndrome: an emerging health risk.
    Razzaq S
    Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
    Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hemolytic uremic syndrome in twin pregnancy at 32 weeks gestation with HELLP syndrome. Case report].
    Pitton MA; Petolillo M; Papi S; Grismondi GL; Masin GP; Forcellini F
    Minerva Ginecol; 2001 Aug; 53(4):279-81. PubMed ID: 11431643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitomycin-induced hemolytic-uremic syndrome.
    Proia AD; Harden EA; Silberman HR
    Arch Pathol Lab Med; 1984 Dec; 108(12):959-62. PubMed ID: 6210069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CML may not be part of HUS.
    Lipton JH; Minden M
    Am J Hematol; 1995 May; 49(1):100-1. PubMed ID: 7741131
    [No Abstract]   [Full Text] [Related]  

  • 39. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
    Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.
    Ladoyanni E; Nambi R
    J Drugs Dermatol; 2005; 4(2):221-2. PubMed ID: 15776781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.